Picrotoxin, an antagonist of 7-aminobutyric acid, produces an increase in coronary vascular resistance, S-T segment elevation, and ventricular arrhythmias after an intravenous injection of 2 mg/kg in chloralose-anesthetized cats. To determine whether these responses were due to blockade of central nervous system GABAergic mechanisms leading to an increase in sympathetic outflow to the coronary vasculature, several types of experiments were performed. First, picrotoxin was injected directly into the brain in a dose of 600 ng while coronary blood flow and S-T segment changes were monitored. Central nervous system administration of this agent resulted in a significant increase in coronary vascular resistance, S-T segment elevation, and arrhythmias. Second, animals were pretreated with the 7-aminobutyric acid receptor agonist drug, muscimol, prior to central administration of picrotoxin. Pretreatment prevented the usual increase in coronary vascular resistance, S-T segment elevation, and arrhythmias. Third, animals were subjected to acute bilateral cardiac sympathetic denervation prior to picrotoxin administration. Denervation attenuated the picrotoxin-induced increase in coronary vascular resistance (mean = 11.6 ± 2.1% vs. 26.1 ± 7.1%, P < 0.05) and elevation in S-T segment (mean = 0.09 ± 0.03 mV vs. 0.29 ± 0.04 mV, P < 0.05), and prevented arrhythmias. Pretreatment with the a-receptor blocking agent, phentolamine, produced even more pronounced antagonistic effects. These results suggest that blockade of central nervous system GABAergic tone leads to enhanced sympathetic outflow to the coronary vasculature, resulting in an increase in coronary vascular resistance of sufficient intensity to cause S-T segment elevation and arrhythmias. {Circ Res 55: [404][405][406][407][408][409][410][411][412][413][414][415]1984) 
IN OUR earlier study (Segal et al., 1981) , we demonstrated that picrotoxin, administered intravenously to chloralose-anesthetized cats, causes an increase in coronary vascular resistance (CVR). This effect was prevented by pretreating animals with the a-adrenergic receptor-blocking agent, phentolamine, suggesting that picrotoxin was acting to increase sympathetic activity to the coronary vasculature. Indeed, data obtained from recording spontaneous occurring sympathetic nerve activity indicate that picrotoxin causes an increase in central sympathetic outflow (Polosa et al., 1969 , DiMicco, 1978 , and this effect appears to be due to the drug acting in the central nervous system (CNS) (Polosa et al., 1969 (Polosa et al., , 1972 DiMicco et al., 1977a; DiMicco, 1978) . In addition, this CNS sympathetic excitatory effect of picrotoxin may be due to blockade of a CNS GABAergic mechanism (Gillis et al., 1980) . The purposes of the present study were to: (1) determine whether the increase in CVR produced by picrotoxin was due to an action of this agent in the CNS, (2) determine whether the effect was due to blockade of CNS GABAergic mechanisms, (3) evaluate further whether peripheral sympathetic nerves were mediating the increase in CVR, and (4) examine the role of peripheral jS-adrenergic receptors in the effect of picrotoxin on CVR.
Methods

General Procedures
Adult cats of either sex weighing 2.0-3.0 kg were anesthetized with chloralose, 70-80 mg/kg, iv. A femoral artery and vein were cannulated for measurement of arterial pressure and for systemic administration of drugs, respectively. The trachea was cannulated, and all animals were artificially ventilated with room air, with a Harvard respirator pump. Animals then were immobilized with decamethonium bromide (Sigma Chemical Co.), 0.25 mg/ kg, iv, given every 45 minutes, or as needed. Rectal temperature was monitored and maintained between 37 and 38°C by an infrared lamp. Arterial pressure and leads I, II, III, aVR, aVL, and aVF of the electrocardiogram (ECG) were recorded using a Statham pressure transducer and needle electrodes, respectively, and monitored continuously on a Gould Brush recorder. In all animals, the cervical vagus nerves were isolated and sectioned bilaterally.
In some experiments, the EEG was recorded. Two small aluminum screws were placed into the spongy part of the parietal bone, bilaterally. These were connected by clips to the electrodes of an ECG. EEG activity was monitored continuously on a Gould Brush recorder.
Access to the heart was achieved through a left (or right) lateral thoracotomy in the 4th or 5th intercostal space, and rib retractors were inserted. The pericardium was cut and sutured to the chest wall. Exposure of the anterior descending branch of the left coronary artery (LAD) and the circumflex artery was made by gently reflecting back the left atrial appendage and separating the epicardial coronary artery from the heart tissue, avoiding interference with the great cardiac vein and pericoronary nerves. Isolation of the right coronary artery was done by carefully separating the tissue at the base of the aorta, thereby exposing the vessel. Coronary blood flow was measured with a Carolina Medical Electronics electromagnetic flow probe (100 series) inserted around the exposed coronary artery. The probe was coupled to a Carolina Medical Electronics square-wave electromagnetic flowmeter (model 501), and the output, both mean and pulsatile flow, was displayed on a Gould Brush recorder. The flow probe was calibrated at Carolina Medical Electronics, and adjustments were made according to the hematocrit of the cat. Coronary vascular resistance was used as a measure of the caliber of the coronary artery. This was calculated as the quotient of diastolic arterial pressure divided by end-diastolic flow and expressed as the percentage change from the baseline. At least 60 minutes were allowed between the time of placing the probe around the vessel and the time of drug testing. In addition, at least 15 minutes of stable recordings of flow, pressure, and heart rate were obtained before drug administration.
Bilateral Cardiac Sympathetic Denervation
The stellate ganglia together with the thoracic sympathetic trunks up to the level of T5 were excised bilaterally through a lateral incision in the 3rd intercostal space. All central and peripheral connections of the ganglia and trunks were similarly removed. In addition, the thoracic vagus and all tissue lying between the sympathetic trunk and the vagus nerve were removed bilaterally.
Intracerebroventricular Administration of Drugs
Animals were mounted in a David Kopf stereotaxic apparatus. The cranium and atlanto-occipital junction were exposed by a midline incision and retraction of the cervical musculature. A small burr hole was made in the skull, the dura was cut, and the tip of a 26-gauge Perfektum spinal needle was stereotaxically placed in the left lateral cerebral ventricle at coordinates Ant. 11.5, HD 8.5, R.L. 4.0, according to the atlas of Snider and Niemer (1961) . A short length of polyethylene tubing was inserted into the cisterna magna to serve as a pressure bleed and exit point for displaced cerebrospinal fluid (CSF). Artificial CSF was prepared according to the method of Merlis (1940) as modified by Feldberg et al. (1970) and used for perfusion and as a solvent for drugs. All drugs were administered in a volume of 0.1 ml, and this was followed by a CSF flush of 0.05 ml. All injections of drug were controlled by administering and flushing the same volumes of CSF containing no drug, or, in the case of picrotoxin, administering a mixture of CSF and ethanol (see below). This control procedure had no significant effect on arterial pressure, coronary vascular resistance, or heart rate and rhythm. Methylene blue was added to the infused CSF to confirm correct placement of the needle at the conclusion of the experiment.
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Lactic Acid Determination
In some experiments, arterial and coronary venous blood samples were collected and analyzed for lactic acid content to determine the myocardial metabolic status. For the collection of-arterial blood, 1 ml was drawn into heparinized syringes from the cannula inserted into the femoral artery, three times per experiment. For the collection of venous blood, 1 ml was drawn into heparinized syringes from a 22-gauge Deseret angiocath inserted into the great cardiac vein and held in place by suturing the angiocath to the chest wall. Again, three samples were collected per experiment.
The blood samples were immediately placed into culture tubes and centrifuged at 3500 g for 15 minutes. Four hundred microliters of plasma were then drawn off of each sample and transferred to another tube. Then, 400 ti\ of 7% perchloric acid were added to each plasma sample to precipitate the plasma proteins, and the tubes were gently vortexed. After a 10-minute incubation period, the samples were again centrifuged at 3500 g for 15 minutes. Four hundred microliters of supernatant were transferred into another tube, and the samples were frozen at -80°C until the assay could be performed. Measurements of lactic acid were made within 7 days after the samples were frozen.
The lactic acid content of the deproteinized plasma samples was assayed by a modification of the method described by Lowry and Passoneau (1972) . In principle, lactic acid was quantified by measuring the absorbance of the NADH formed when lactate is converted to pyruvate. A 50 ITIM 2-amino 2-methyl-propranol buffer was used. This was composed of both the free base and the hydrochloride (free acid), and had a pH of 9.8-9.9.
The assay procedure was as follows: 900 ti\ of buffer, to which NAD (Boehringer-Mannheim) was added (1.8 mg/ml buffer), were placed in each tube; 20 p\ of 50 mM glutamate (Sigma) (adjusted to pH 9.9 with NaOH) were then added to each tube, and the tubes were gently vortexed. Next, 50 /A of each thawed plasma sample were added to the appropriate tubes, which were again vortexed. Ten microliters of glutamic-pyruvic transaminase (Boehringer-Mannheim), followed by 20 iA of lactic dehydrogenase (Boehringer-Mannheim), were then added to each tube, which were gently vortexed after each addition. The tubes were allowed to incubate for 15 minutes at room temperature. The absorbance of each tube was read at 340 nm, with a Gilford 250 spectrophotometer. A standard curve was constructed from values obtained when known amounts of lactic acid dissolved in buffer + NAD and 400 p\ of perchloric acid were added to the tubes and carried through the assay. Blanks were obtained by substituting distilled water for the plasma sample and carrying the "empty" sample through the assay procedure. All samples, standards, and blanks were done in duplicate.
Myocardial lactate utilization was determined using the following ratio: (Ca -Cv)/Ca, and expressed as a percent, where Ca = arterial lactate concentration (in mg/100 ml, obtained from standard curve), and Cv = coronary venous concentration (in mg/100 ml, obtained from standard curve). A positive value indicates net myocardial lactate extraction, and a negative value indicates net myocardial lactate production (Buffington and Feigl, 1981) .
Drugs
Drugs used were as follows: a-chloralose (Etablissement Kuhlmann) was prepared by dissolving in boiling distilled water. The solution then was cooled down to body temperature before injection. Picrotoxin (Aldrich Chemical Co.) was prepared by first dissolving 30 mg in 1.0 ml of absolute ethanol and then diluting up to a final volume of 10 ml with artificial CSF. The picrotoxin solution was made fresh daily and protected from light until ready for use.
Phentolamine hydrochloride (Regitine) (Ciba-Geigy Corp.), d,/-propranolol hydrochloride (Sigma Chemical Co.), bicuculline methiodide (Pierce Biochemicals), and muscimol (Biosearch) all were dissolved in either saline or artificial CSF. The dose of phentolamine used was 5 mg/ kg, given iv. This dose was chosen because it blocked an increase in mean blood pressure of 50-60 mm Hg, produced by a 0.1 jig/kg dose of norepinephrine (iv). The dose of propranolol used was 1 mg/kg, given iv. This dose was chosen because it blocked the increase in heart rate of 40-50 beats/min produced by a 0.1 Mg/kg dose of isoproterenol (iv). Doses of picrotoxin, bicuculline, and muscimol were chosen based on results obtained from our earlier studies (Gillis et al., 1980) . Vasopressin (Pitressin) (Parke-Davis) solution was used as prepared commercially. The vasopressin antagonist [l-(/3-mercapto-|8,/3-cyclopentamethylenepropionic acid), 2-(0-methyl)tyrosine] arginine vasopressin [d(CH 2 )5 tyr(Me)AVP) was obtained from Bachem. This agent was dissolved in saline.
Statistical Analyses
Statistical tests used included grouped and paired ttests, analysis of variance with Duncan's new multiple range test, and x 2 analysis using the Yates correction factor. The criterion for statistical significance was P < 0.05. All values are expressed as the mean ± SEM.
Results
Effect of Central Administration of Picrotoxin on CVR
Picrotoxin (600 /ig) was administered into the left lateral cerebral ventricle of nine animals while blood flow was being monitored in the anterior descending branch of the left coronary artery. An increase in CVR occurred in each animal, and the data are summarized in Table 1 . The peak change in resist-Circulation Research/Vol. 55, No. 3, September 1984 ance occurred, on the average, 4.2 minutes after injection, and resistance remained elevated for the duration of the experiment (40-60 minutes) in six of the nine animals studied. The duration of the increase in CVR in the remaining three animals averaged 2.7 minutes and was superceded by a drop in CVR averaging 36% below predrug baseline that persisted for an average of 24.3 minutes. Each animal exhibited S-T segment elevation, which occurred after the peak coronary constrictor effect was noted [mean of 7.1 minutes after picrotoxin administration (see Table 1 )]. S-T segment elevation persisted for an average of 26 minutes.
Six of the nine animals developed cardiac rhythm disturbances; four of these had intermittently occurring premature ventricular contractions starting at 5-7 minutes after picrotoxin administration, and two had more prolonged ventricular arrhythmias (i.e., bigeminy and multifocal tachycardia). In these latter two animals, the arrhythmias began at 3 and 9 minutes after drug administration, and had a duration of 4 and 6 minutes, respectively. In both of these animals, the arrhythmias began immediately after a sharp drop in picrotoxin-induced increase in CVR was observed.
Increases in arterial pressure and sinus rate were also observed with central administration of picrotoxin (see Table 1 ). Peak increases in both of these indices of cardiovascular function occurred a few minutes after the peak increase in CVR was noted. An experiment illustrating the time course of the cardiovascular changes seen with picrotoxin is shown as part of Figure 1 . The data used for making this figure were obtained from the animal showing the greatest change in CVR with picrotoxin administration.
Picrotoxin is well known to produce seizure activity (Wang and Ward, 1977) , and seizures per se can influence cardiovascular function (Brown et al., 1953) . In each case, seizure activity was evoked with picrotoxin administration, and the time to onset for +0.20 ± 0.02* (8.3 ± 1.5) Incidence of arrhythmias 6/9 (4=PVC's) (6.3 ± 1.8) 2/5 (3.5 + 0.5) 2/4 (6.5 ± 0.5) Incidence of seizures 9/9 (9.5 ± 1 5/5 (8.8 ± 2 4/4 (9.3 ± 1 this response averaged 9.5 minutes after the drug was injected. EEG activity consisted of short bursts of high frequency low amplitude spikes, followed by high amplitude low frequency spikes that persisted for the duration of the experiment. Picrotoxin was also administered to five animals while blood flow was monitored in the circumflex branch of the left coronary artery, and to four animals while blood flow was monitored in the right coronary artery. As in the case of the anterior descending coronary artery, picrotoxin administration produced an increase in CVR in each animal tested (see data, Table 1 ). This increase ranged from 3 to 100% with an average value of 31.8% in the circumflex flow studies, and 9 to 56% with an average value of 37.3% in the right coronary flow studies.
In the circumflex flow studies, the peak change in resistance occurred approximately 5.0 minutes after injection, and resistance remained elevated for the duration of the experiment (40-60 minutes) in two of the five animals studied. The duration of the increase in CVR in the remaining three animals averaged 5 minutes, and was superceded by a drop in CVR averaging 42% below pre-drug baseline. In one animal, the flow actually dropped to zero, signifying total occlusion. When flow returned, there was an overshoot relative to the preocclusion value.
The experimental data from this particular animal are shown in Figure 2 .
Each animal exhibited S-T segment elevation after the peak increase in CVR was noted ( Table 1) . Two of the five animals exhibited ventricular tachyarrhythmias that began 3 and 4 minutes after picrotoxin administration and had a duration of 4 and 6 minutes, respectively. Characteristic pressor and tachycardic responses were again observed in this group of animals (Table 1) . Again, these changes did not become maximal until after the peak increase in CVR was observed.
In the right coronary flow studies, the peak change in resistance occurred approximately 9.0 minutes after drug injection, and resistance remained elevated for the duration of the experiment (20-60 minutes) in three of the four animals studied. The duration of the increase in CVR in the remaining animal was 7 minutes and was superceded by a drop in CVR of 26% below pre-drug baseline.
Three animals exhibited S-T segment elevation, and the fourth animal exhibited S-T segment depression (Table 1 ). The average time to onset of S-T segment changes was 8.3 minutes after picrotoxin administration, and these changes persisted, on the average, for 31.0 minutes. Two of the four animals developed cardiac rhythm disturbances (ventricular tachycardia) that had an onset of 7 minutes and a duration of 1 and 4 minutes. Characteristic pressor and tachycardic responses were again observed (Table 1).
Lactic acid determinations were performed in five additional animals that received an injection of 600 Hg of picrotoxin into the lateral ventricle. Venous blood was collected from the great cardiac vein just prior to picrotoxin administration, approximately at the time of maximal elevation in the S-T segment (i.e., between 5 and 10 minutes after picrotoxin administration), and 60 minutes after picrotoxin had been administered. Arterial blood from the femoral artery was also collected at these times.
The results of these experiments (data indicated for animals 4 through 8) are shown in Table 2 . Reduced lactate extraction and/or net lactate production ranging from 11 to 67% was observed in every picrotoxin-treated animal at the approximate time of peak S-T segment change. Two animals exhibited decreased lactate extraction, while three animals exhibited net lactate production. The net change in lactate was +32.6 ± 9.5%, and this change was statistically significant (Table 2) .
Three animals served as controls and are listed as animals 1 to 3 in Table 2 . In these studies, the vehicle used for picrotoxin injection was administered into the lateral ventricle, and blood samples were drawn at times corresponding to the sampling times in the picrotoxin experiments. The control animals exhibited an average net change of only 6.3 ± 0.9% less lactate extraction and/or production at the time max- (600 ng imal S-T elevation was normally seen in the picrotoxin-treated animals. Finally, to determine whether the 600-^g dose of picrotoxin administered into the lateral ventricle could have produced some or all of its effects by leakage out of the CNS and into the periphery, this dose was given intravenously to three animals. In each instance, no changes in CVR, S-T segment, cardiac rhythm, arterial pressure, heart rate, and the EEG occurred after systemic administration of picrotoxin.
Effect of Surgical and Pharmacological Denervation of the Sympathetic Nervous System on Picrotoxin-Induced Increases in CVR
Picrotoxin (600 ng) was administered into the left lateral cerebral ventricle of seven animals subjected to bilateral sympathetic denervation, and to five animals pretreated with the a-adrenergic receptorblocking agent, phentolamine (see data, Table 3 ).
Focusing on the surgical denervation studies, this intervention significantly (P < 0.05) attenuated the increase in CVR normally seen with picrotoxin administration (Table 3 ). The increases in CVR ranged from 3 to 20%, with an average value of 11.6%. The peak change in resistance occurred approximately 4 minutes after injection, and resistance remained elevated for the duration of the experiment (30-40 minutes) in three of the seven animals studied. The duration of the increase in CVR in the remaining four animals averaged 7.3 minutes, and was superceded by a drop in CVR that averaged 20.5% below pre-drug baseline. Only four of the seven animals exhibited S-T segment changes, the magnitude of which was also significantly (P < 0.05) attenuated from that observed in the control animals ( Table 3) . None of the seven animals exhibited cardiac rhythm disturbances (Table 3 ). The characteristic pressor and sinus tachycardic responses were still observed in these animals, although the increase in sinus rate was, surprisingly, significantly (P < 0.05) higher and peaked significantly (P < 0.05) later in the denervated animals, compared to the control animals (Table 3) .
The cardiovascular responses to picrotoxin of sympathetically denervated animals, compared to a control animal, are illustrated in Figure 1 . This figure graphically depicts the attenuation of the CVR and S-T segment changes by cardiac sympathetic denervation. Denervation, per se, resulted in a significant (P < 0.05) reduction in heart rate but no significant change in arterial pressure (Table 3 ). The effect of denervation on CVR was not examined, because the flow probe was not positioned on the vessel until after the denervation had been performed.
Focusing on the pharmacological denervation studies, the first drug we tested was the a-receptorblocking agent, phentolamine. This agent, in a dose of 5 mg/kg, was administered, iv, 15 minutes before picrotoxin was administered into the CNS. Pretreatment with phentolamine resulted in a significant reduction in arterial pressure, but we noted no changes in heart rate (Table 3) or CVR (not shown). Phentolamine pretreatment completely prevented the increase in CVR normally observed with picrotoxin. Only a decrease in CVR occurred, ranging from 10 to 41%, with an average value of 29.8% (Table 3 ). The peak drop in resistance occurred approximately 21 minutes after injection, which is significantly later than the peak increase in CVR observed in the control animals (Table 3) . Similarly, phentolamine completely prevented the occurrence of S-T segment changes and cardiac rhythm disturbances (Table 3) . Finally, the pressor response normally elicited by picrotoxin was attenuated, but the difference was not statistically significant (P > 0.05). However, the tachycardic response was significantly (P < 0.05) attenuated, and it also occurred at a significantly (P < 0.05) later time than that seen in the control animals.
To determine whether phentolamine might be counteracting the ischemic effect of picrotoxin by acting nonspecifically on the coronary vessels and/ or the heart, we used the coronary constrictor agent vasopressin in three experiments, administering 5 units/kg, iv, over 30 seconds, 15 minutes after phentolamine pretreatment. This produced pronounced increases in CVR, averaging +86 ± 26%, in each animal tested. Each of the three animals exhibited ventricular arrhythmias. Vasopressin given alone to eight animals caused an increase in CVR of 118 ± 28%, and four of the eight animals exhibited ventricular arrhythmias. There was no statistically sig-nificant difference between the increases in CVR induced by vasopressin in the two groups.
The second drug tested was the /8-receptor-blocking agent, propranolol. This agent was administered iv in a dose of 1 mg/kg, 20-30 minutes before picrotoxin was administered into the CNS. Pretreatment with propranolol resulted in significant decreases in both arterial pressure and heart rate (Table  3) , but no change in CVR was noted (not shown).
Pretreatment with propranolol did not prevent the picrotoxin-induced increases in CVR. We observed an increase ranging from 15 to 43% [mean value of 25% (Table 3) ] approximately 6.3 minutes after injection. Resistance remained elevated for the duration of the experiment (50-60 minutes) in three of the four animals studied. The duration of the increase in CVR in the remaining animal was 4 minutes, and was superceded by a drop in CVR of 53% below the pre-drug baseline. Propranolol pretreatment also failed to prevent the occurrence of picrotoxin-induced S-T segment changes, although the time to onset of these changes was significantly (P < 0.05) later than that seen in the control animals ( Table 3) . This is probably due to the fact that every one of these animals exhibited a ventricular tachyarrhythmia (i.e., bigeminy and/or ventricular tachycardia), and the S-T segment changes were not apparent until sinus rhythm returned. The arrhythmias began at 2-7 minutes after drug administration and lasted 4-25 minutes. Propranolol pretreatment did not alter the magnitude of the characteristic pressor and tachycardic responses. However, both of these indices peaked significantly (P < 0.05) later than in the control animals ( Table 3) .
Role of CNS GABAergic Mechanisms in the . Increase in CVR Induced by Picrotoxin
Since picrotoxin is known to be an antagonist of GABA-induced neural effects (Johnston, 1976) , the role of CNS GABAergic mechanisms in the increase in CVR induced by picrotoxin was studied, utilizing two different approaches. First, the ability of another GABA antagonist, bicuculline, to induce an increase in CVR and subsequent myocardial ischemic changes similar to those observed with picrotoxin was tested. Second, the ability of the GABA receptor agonist drug, muscimol (Johnston, 1976) to block the increase in CVR observed with picrotoxin administration was examined.
Focusing on the bicuculline studies, 25 ng of bi-cuculline methiodide (BMI) were administered centrally every 30 seconds for a total dose of 100 /xg to five animals. BMI was used because it is ionized at physiological pH and would presumably not cross the blood-brain barrier and act at peripheral sites. This dose was chosen because it fell within the range of doses previously shown to produce sympathetically mediated cardiovascular effects in chloraloseanesthetized cats (DiMicco and Gillis, 1979) . The 100-^g dose was split into four injections because preliminary experiments showed that 100 /*g given as a bolus evoked a pressor response that was too intense and occurred too rapidly to be able to distinguish any increases in CVR. The results of these experiments are summarized in Table 4 . As did picrotoxin, BMI produced a significant increase in CVR (Table 4 ). The peak change in CVR occurred approximately 1.5 minutes after the start of injection, and resistance remained elevated for the duration of the experiment in three of the five animals studied. In the remaining two animals, the initial increase in CVR was superseded by a decrease of 16 and 36% below pre-drug baseline, which occurred simultaneously with the maximal hypertensive and tachycardic responses. Each animal also exhibited S-T segment elevation (Table 4 ). Two of the five animals developed cardiac rhythm disturbances consisting of multifocal ventricular tachycar- dia. The characteristic pressor and tachycardic responses were also observed with centrally administered BMI (Table 4 ).
In the muscimol studies, four animals were pretreated with 20 ^g of muscimol administered into the lateral ventricle, 20 minutes before they were given 600 ng of picrotoxin, icv. This dose was chosen because Gillis et al. (1980) showed it to be an effective amount for antagonizing picrotoxin-induced bradycardia and hypotension normally seen in chloralose-anesthetized cats with vagus nerves intact. The data from these four animals are summarized in Table 5 . Muscimol pretreatment always produced decreases in arterial pressure and heart rate ( Table 5) . No significant change in CVR was noted (not shown).
Twenty micrograms of muscimol completely prevented the increase in CVR normally seen after central administration of picrotoxin (Table 5) . Furthermore, no S-T segment changes, cardiac rhythm disturbances, or increases in blood pressure and heart rate were observed in any of these animals ( Table 5) . Feldberg (1976) reported that picrotoxin administration can cause release of vasopressin into the circulation, and it is well known that vasopressin has a powerful constrictor effect on coronary vessels (e.g., Heyndrickx et al., 1976) . To determine whether vasopressin release was involved in the myocardial ischemic effects of picrotoxin, we pretreated three animals with a 30-^ig iv bolus dose of the vasopressin antagonist,
Role of Vasopressin Release in the Increase in CVR Induced by Picrotoxin
[l-(jS-mercapto-/3,j8-cyclopentamethylenepropionic acid), 2-(0-methyl)tyrosine] arginine vasopressin [d(cH 2 )5 tyr(Me)AVP]. We based our choice of this dose on the findings of Berecek and colleagues (1983) , showing blockade of the pressor effects of vasopressin in rats. Cats were given 30 fig of the vasopressin antagonist, and 15 minutes later were challenged with an intracerebral injection of 600 ng of picrotoxin. The effect of picrotoxin was unaltered, inasmuch as an increase in CVR of 27.0 ± 11.0% occurred, and each animal developed a ventricular arrhythmia. Our hypothesis that a bolus iv dose of 30 fig of the vasopressin antagonist was, in fact, blocking vasopressin in our system was tested by determining the response of the coronary vasculature to iv vasopressin given as 5 units/kg over 30 seconds. As mentioned, this dose of vasopressin alone increases CVR by 118 ± 28%. Pretreatment with the vasopressin antagonist 15 minutes before challenge with vasopressin completely prevented the coronary constrictor effect of vasopressin. Indeed, there was a decrease in CVR of 27.5 ± 3.5%.
Discussion
The new findings of this study are: (1) picrotoxin administered into the CNS of chloralose-anesthetized cats produces an increase in CVR in each of the three major coronary arteries; (2) picrotoxininduced increases in CVR are associated with reduced lactate extraction and/or net lactate production; (3) acute cardiac sympathetic denervation counteracts picrotoxin-induced increases in CVR, S-T segment elevation, and cardiac arrhythmias; (4) pretreatment with propranolol does not counteract picrotoxin-induced increases in CVR, S-T segment elevation, or cardiac arrhythmias; (5) bicuculline, a CNS GABAergic antagonist, also causes an increase in CVR after CNS administration; and (6) pretreatment with the CNS GABAergic agonist drug, muscimol, prevents picrotoxin-induced increases in CVR, S-T segment elevation, and cardiac arrhythmias.
Our data suggest that picrotoxin might have an effect that selectively enhances sympathetic outflow to the coronary vessels. This is suggested by the time-action curve data, where an increase in CVR was observed as the first event, and the peak increase in CVR was noted before major changes in heart rate, cardiac rhythm, and arterial pressure developed. By reducing the dose of picrotoxin administered into the brain (specifically, into the 4th ventricle) from 600 to 200 fig, it is possible in selected experiments to observe an increase in CVR without observing significant changes in heart rate and arterial pressure (Segal, 1982) . The latest occurring event was seizure activity, and this was noted on the average of 9.5 minutes after drug administration. The late occurrence of this event suggests that the increase in CVR and other cardiovascular changes induced by picrotoxin occur independently of the seizures.
The mechanism of action of picrotoxin on the coronary vasculature appeared to be related to blockade of CNS GABAergic mechanisms, and the response appeared to be mediated in part by the cardiac sympathetic nerves. Evidence for the former was obtained from studies with the classic GABAreceptor antagonist drug, bicuculline, and the GABA-receptor agonist drug, muscimol. Bicuculline methiodide infused into the cerebroventricles was found to evoke the same type of cardiovascular responses observed with picrotoxin, namely, an increase in CVR, S-T segment elevation, and arrhythmias. We found that pretreatment by administering muscimol into the cerebroventricles completely prevented the increase in CVR, as well as the other cardiovascular responses normally seen with centrally administered picrotoxin. Evidence for the latter was obtained from studies in which acute bilateral cardiac sympathetic denervation was performed. This intervention significantly attenuated the increase in CVR induced by central administration of picrotoxin. The resistance increase was attenuated by approximately 45%, and the magnitude of the S-T segment changes, by approximately 31%.
The increase in CVR and S-T segment elevation remaining after cardiac sympathetic denervation also appeared to be due to a catecholamine action on a-adrenergic receptors of the coronary vascular bed. Evidence for this hypothesis was obtained from the studies using the a-adrenergic receptor-blocking agent, phentolamine. Pretreatment with this agent completely prevented a picrotoxin-induced increase in CVR, S-T segment elevation, and cardiac arrhythmias. The source of the catecholamines might be the adrenal gland. This possibility is suggested by the heart rate data in the present study, as well as heart rate data from our earlier study. In the present study, sinus rate was observed to increase by 33 beats/min, 5.3 minutes after picrotoxin had been administered to animals with intact cardiac sympathetic nerves. An increase in sinus rate also was observed in animals subjected to cardiac sympathetic denervation, but this increase occurred significantly later than in the control animals (i.e., peak response noted at 12 minutes after picrotoxin administration), and might have resulted from the action of augmented circulating catecholamines released from the adrenal glands. Consistent with this notion are the results of our earlier study (DiMicco et al., 1977b) , showing the occurrence of a significant increase in sinus rate with picrotoxin administration after bilateral stellate ganglionectomy, but abolition of the response by combined bilateral stellate ganglionectomy and adrenalectomy. Hence, the residual increase in CVR and S-T segment elevation observed in cardiac sympathetic denervated animals may have resulted from an action of catecholamines released from the adrenal glands. Presumably, the adrenal gland release was due to an action of picrotoxin in the CNS.
It is known that picrotoxin administration can cause release of vasopressin into the circulation (Feldberg, 1976) . In view of this releasing effect, and in view of the fact that vasopressin exerts a powerful constrictor effect on the coronary vessels (Heyndrickx et al., 1976) , we considered the possibility that vasopressin might be playing a role in picrotoxin-induced myocardial ischemia. This was examined in two ways. First, pretreatment of cats with a vasopressin antagonist had no effect on the increase in CVR induced by picrotoxin. Second, the increase in CVR induced by vasopressin, 5 units/kg, iv, was not affected by pretreatment with phentolamine. However, myocardial ischemia produced by picrotoxin was completely prevented by pretreatment with phentolamine. These findings would tend to exclude a role for vasopressin in picrotoxin-induced myocardial ischemia.
The intensity of the coronary constrictor response obtained with picrotoxin was considerable, especially in view of the fact that it was occurring at a time when a large metabolic demand was being placed on the heart. This is clear from data obtained with S-T segment measurements, cardiac rhythm analysis, and lactic acid measurements. S-T segment elevation was one of the most consistent changes observed with picrotoxin, and is characteristic of myocardial ischemia caused by coronary constriction. This relationship was shown by Prinzmetal and colleagues (1961) and Ekmekei et al. (1961) , who occluded a major coronary vessel in dogs with a ligature and observed S-T segment elevation in the surface ECG. It was again verified by Uchida and colleagues (1978) , who showed S-T elevation corresponding with cyclical reductions in coronary blood flow. A somewhat less consistent response was the occurrence of ventricular arrhythmias. These were observed in 10 of the 18 control animals in which blood flow was measured from one of the three major coronary vessels and in four of four animals in which propranolol pretreatment was employed. We interpret these arrhythmias as being due to the ischemia produced by coronary constriction or build-up of noxious substances in the blood that are widely distributed throughout the heart with improved cardiac perfusion. Our interpretation is based in part on the time course data. Tachyarrhythmias evoked by picrotoxin always occurred after an increase in CVR had developed. These arrhythmias were associated either with the time of peak increase in CVR (in some cases) or, in other instances, with an abrupt decrease in the initial CVR response (i.e., after coronary reperfusion). Additional evidence for increases in CVR being responsible for picrotoxininduced arrhythmogenesis is that rhythm disturbances were never observed in animals in which increases in CVR were prevented. This was the case with pretreatment with phentolamine. It was also the case with bilateral cardiac sympathetic denervation, where significant attenuation of picrotoxininduced CVR changes was observed and no arrhythmias were noted.
The lactate content in arterial and coronary venous blood was measured in five animals; reduced lactate extraction was observed in two animals, whereas net lactate production was observed in the other three animals. The percentage of lactate extracted from arterial blood in normally oxygenated myocardium has been found to be between 26 and 46% in other studies (Shea et al., 1962; Case et al., 1969; Opie et al., 1973) . During myocardial ischemia induced experimentally by mechanical constriction of the coronary arteries or the aorta in dogs, other investigators found reductions in myocardial lactate extraction of approximately 20% (Opie et al., 1973) , 31% (Shea et al., 1962) , 13% (Case et al., 1969) , and 21% (Griggs and Chen, 1974) . Net myocardial lactate production averaging 6.9 mg/100 ml was reported in one study at the time of peak reduction in coronary blood flow (Shea et al., 1962) . Net myocardial lactate production of 4.3, 4.7, and 10.4 mg/ 100 ml was observed in three animals in the present study. Buffington and Feigl (1981) found that myocardial lactate extraction decreased by approximately 30% during coronary vasoconstriction induced by norepinephrine in dogs, but net myocardial lactate production never occurred. Therefore, the changes in lactate metabolism induced by picrotoxin in the present studies are even more striking, compared with data obtained by others.
It is therefore apparent that picrotoxin induces an 413 increase in CVR that is severe enough to produce myocardial ischemia, even in the presence of increased myocardial oxygen demand. Indeed, there seemed to be competition between picrotoxin-induced vasoconstriction and metabolic vasodilation.
In roughly one-half of the animals tested, a drop in CVR of 10-40% below pre-drug baseline was observed following the initial increase in CVR. This secondary coronary vasodilation occurred at the same time that peak increases in arterial pressure and sinus rate were observed. However, in approximately half of the animals tested, the increase in CVR was maintained throughout the experiment. This suggests that the picrotoxin-induced increases in CVR were a primary response, and were strong enough, in at least half of the cases, to override the secondary metabolically induced coronary vasodilation observed in response to increased myocardial oxygen demand. Pretreatment with phentolamine had several important effects on the picrotoxin-induced responses, and we interpret most of them as being due to blockade of peripheral a-adrenergic receptors on the coronary arteries. Receptor blockade explains the prevention of CVR changes and subsequent S-T segment elevation and arrhythmias. However, phentolamine has been described as having an antiarrthythmic effect that may be independent of a-receptor blockade (Rosen et al., 1971; Casscells et al., 1979) , and this effect may contribute to lack of arrhythmias noted in animals pretreated with this agent. This contribution must be minimal, since bilateral cardiac sympathetic denervation also prevented the arrhythmias.
Animals pretreated with phentolamine exhibited only a decrease in CVR after picrotoxin administration. This coronary vasodilation probably occurred in response to an increased myocardial metabolic demand, since picrotoxin still induced an increase in heart rate in these animals, and, although it was not measured, contractile force probably was also increased. In addition, a significant increase in arterial pressure was still produced in these animals by picrotoxin. This increase in pressure could cause passive dilation of the coronary arteries (Berne and Rubio, 1979 ).
An interesting observation from the present studies, and one that lends further, though indirect, support to the a-adrenergic receptor mechanism of the picrotoxin-induced increase in CVR, is that blockade of /3-adrenergic receptors with propranolol did not prevent the picrotoxin-induced changes in CVR, or the subsequent ischemic ECG changes and arrhythmias. In fact, the incidence and severity of arrhythmias appeared greater in the propranololpretreated animals than in the control animals. These results fit with our earlier findings indicating that pretreatment with propranolol and practolol had no effect on the incidence of arrhythmias produced by intravenously administered picrotoxin (DiMicco et al., 1977b) . The increased incidence and severity of picrotoxin-induced arrhythmias in propranolol-pretreated animals may be due to more intense myocardial ischemia produced by an unopposed a-receptor-mediated increase in CVR. Another possibility for the enhanced arrhythmogenic response in the propranolol-pretreated animals is that any increase in contractile force induced by picrotoxin could have been blocked by propranolol. This would eliminate some of the stimuli for metabolically mediated vasodilation, leaving the a-receptor-mediated increase in CVR unopposed.
Some of the important conclusions made in this study are based on calculated coronary resistance using the quotient of end-diastolic aortic pressure divided by the end-diastolic flow. This method of expressing changes in coronary arterial tone is controversial, because it does not take into account intracoronary flow-dependent pressure gradients, extravascular compressive forces, changes in diastolic ventricular pressures, changes in critical closing pressure, and transmural variations in the above parameters (Marcus, 1983) . However, we have observed similar changes in coronary vascular resistance with picrotoxin in cats with arterial pressure maintained at a constant value by using a pressurized reservoir attached to the abdominal aorta (Segal and McKenzie, unpublished observations) . In addition, in some of these animals, heart rate did not change appreciably. Thus, changes in driving pressure and extravascular forces (created by an increased heart rate) do not appear to be responsible for the increase in coronary vascular resistance that we observed in the present studies. We do not have information on changes in back pressure that may be occurring during the picrotoxin-induced response, and this factor could influence intracoronary flow-dependent pressure gradients and the interpretation of our data.
